Answers are grounded in this paper and cite their sources.
In this study, using low-toxicity and easily accessible aryl-substituted tertiary cycloalkanols as starting materials, the precise C-H functionalization at the C6 position of azauracils is efficiently achieved under silver-catalyzed conditions. This strategy features operational simplicity, a broad substrate scope covering aryl-substituted tertiary cycloalkanols and diversely substituted azauracils, and high compatibility with azauracil cores fused to pharmaceutical scaffolds, thus affording an efficient approach to expanding the structural diversity of azauracils.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: